Evidence for the use of vilazodone in the treatment of major depressive disorder

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 15, 2012, Pages 2215-2224

  Reinhold, Jennifer A ^a   Mandos, Laura A ^a   Lohoff, Falk W ^b   Rickels, Karl ^b  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

5 HT1A receptor; Major depressive disorder; Selective serotonin reuptake inhibitors (SSRIs); Sexual dysfunction; Vilazodone

Indexed keywords

CITALOPRAM; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; FLUOXETINE; KETOCONAZOLE; PLACEBO; SEROTONIN 1A RECEPTOR; SEROTONIN UPTAKE INHIBITOR; VILAZODONE;

AREA UNDER THE CURVE; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DIARRHEA; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DSM-IV-TR; ELECTROCARDIOGRAM; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HAMILTON SCALE; HEADACHE; HEART RATE; HUMAN; LABORATORY TEST; LIBIDO DISORDER; LIVER METABOLISM; MAJOR DEPRESSION; MAXIMUM PLASMA CONCENTRATION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY (TOPIC); NAUSEA; NONHUMAN; OPTIMAL DRUG DOSE; ORGASM; PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICAL EXAMINATION; PR INTERVAL; QRS COMPLEX; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; SEXUAL FUNCTION; SIDE EFFECT;

ANIMALS; ANTIDEPRESSIVE AGENTS; BENZOFURANS; DEPRESSIVE DISORDER, MAJOR; HUMANS; INDOLES; PIPERAZINES;

EID: 84866490079     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.721776     Document Type: Article

References (36)

1. Gelenberg AJ, Freeman MP, Markowitz JC, et al. Practice guideline for the treatment of patients with major depressive disorder. 3rd edition. American Psychiatric Association 2010
2. Rizvi SJ, Kennedy SH. Emerging drugs for major depressive disorder: an update. Expert Opin Emerg Drugs 2012;17(3):285-94
3. Nutt DJ. Highlights of the international consensus statement on major depressive disorder. J Clin Psychiatry 2011;72(6):e21
4. Schulberg HC, Katon W, Simon GE, et al. Treating major depression in primary care practice: an update of the Agency for Health Care Policy and Research Practice Guidelines. Arch Gen Psychiatry 1998;55(12):1121-7 (Pubitemid 28558285)
5. Reed CR, Kajdasz DK, Whalen H, et al. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder. Curr Med Res Opin 2012;28(1):27-39
6. Kupfer DJ, Frank E, Phillips ML. Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet 2012;379(9820):1045-55
7. Westenberg HG, Sandner C. Tolerability and safety of fluvoxamine and other antidepressants. Int J Clin Pract 2006;60(4):482-91
8. Peretti S, Judge R, Hindmarch I. Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl 2000;403:17-25
9. Sarko J. Antidepressants, old and new. A review of their adverse effects and toxicity in overdose. Emerg Med Clin North Am 2000;18(4):637-54
10. Mandrioli R, Mercolini L, Saracino MA, et al. Selective Serotonin Reuptake Inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions. Curr Med Chem 2012;19(12):1846-63
11. Strohmaier J, Wust S, Uher R, et al. Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: clinical description and the role of the 5-HTTLPR. World J Biol Psychiatry 2011;12(7):528-38
12. Werneke U, Northey S, Bhugra D. Antidepressants and sexual dysfunction. Acta Psychiatr Scand 2006;114(6):384-97 (Pubitemid 44707066)
13. Schweitzer I, Maguire K, Ng C. Sexual side-effects of contemporary antidepressants: review. Aust NZ J Psychiatry 2009;43(9):795-808
14. Breen R, McCormac RJ. A fresh look at management of depression. How to choose and use the newer antidepressant drugs. Postgrad Med 2002;112(3):28-30; 33-4, 37-40
15. Howland R.H. Sequenced Treatment Alternatives to Relieve Depression (STAR D). Part 2: study outcomes. J Psychosoc Nurs Ment Health Serv 2008;46(10):21-4
16. Gibbons RD, Hur K, Brown CH, et al. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012; Epub ahead of print
17. Undurraga J, Baldessarini RJ. Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review. Neuropsychopharmacology 2012;37(4):851-64
18. Leucht S, Hierl S, Kissling W, et al. Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry 2012;200(2):97-106
19. Bech P. Is the antidepressive effect of second-generation antidepressants a myth? Psychol Med 2010;40(2):181-6
20. Khan A. Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression. Expert Opin Investig Drugs 2009;18(11):1753-64
21. Celada P, Puig M, Amargos-Bosch M, et al. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci 2004;29(4):252-65 (Pubitemid 39185866)
22. Olver JS, Cryan JF, Burrows GD, et al. Pindolol augmentation of antidepressants: a review and rationale. Aust NZ J Psychiatry 2000;34(1):71-9 (Pubitemid 34692848)
23. Hughes ZA, Starr KR, Langmead CJ, et al. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur J Pharmacol 2005;510(1-2):49-57 (Pubitemid 40312389)
24. Artigas F, Adell A, Celada P. Pindolol augmentation of antidepressant response. Curr Drug Targets 2006;7(2):139-47
25. Frampton JE. Vilazodone: in major depressive disorder. CNS Drugs 2011;25(7):615-27
26. Laughren TP, Gobburu J, Temple RJ, et al. Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant. J Clin Psychiatry 2011;72(9):1166-73
27. Owen RT. Vilazodone: a new treatment option for major depressive disorder. Drugs Today (Barc) 2011;47(7):531-7
28. US Food and Drug Administration. Drug Approval Package. Viibryd (vilazodone hydrochloride) Tablets. 2011. Available from: http://www.accessdata. fda.gov/drugsatfda-docs/nda/2011/022567Orig1s000TOC.cfm [Accessed 26 April 2012]
29. Viibryd (vilazodone) [prescribing information]. - 2012 Forest Laboratories, Inc; NY
30. de Paulis T. Drug evaluation: vilazodone-a combined SSRI and 5-HT1A partial agonist for the treatment of depression. IDrugs 2007;10(3):193-201 (Pubitemid 46438428)
31. Rickels K, Athanasiou M, Robinson DS, et al. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70(3):326-33
32. Khan A, Cutler AJ, Kajdasz DK, et al. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry 2011;72(4):441-7
33. Robinson DS, Kajdasz DK, Gallipoli S, et al. A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder. J Clin Psychopharmacol 2011;31(5):643-6
34. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
35. Asberg M, Montgomery S, Perris C, et al. A comprehensive psychopathological rating scale. Acta Psychiatr Scand 1978;S271:24-8
36. Guy W. ECDEU Assessment Manual for Psychopharmacology - Revised (DHEW Publ No ADM 76-338). U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; Rockville, MD: 1976